Somewhat Positive Press Coverage Somewhat Unlikely to Affect Illumina (ILMN) Stock Price
News headlines about Illumina (NASDAQ:ILMN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Illumina earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the life sciences company an impact score of 46.8491055476259 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Telegraph Partners and Illumina form Verogen (pehub.com)
- Illumina and SF-Based Venture Firm Launch in San Diego (biospace.com)
- Illumina Inc Up 38.2% Since SmarTrend Uptrend Call (ILMN) (mysmartrend.com)
- Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market (finance.yahoo.com)
- Illumina, Inc. (NASDAQ:ILMN) Stock Closed 7.1% Above Its 50 Day Moving Average – Highlight Press (highlightpress.com)
ILMN has been the topic of several recent analyst reports. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Vetr cut shares of Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 price target on the stock. in a report on Wednesday, August 2nd. Barclays PLC reaffirmed an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Finally, Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and upped their price target for the company from $170.00 to $215.00 in a report on Monday, August 7th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $177.01.
Illumina (ILMN) traded down 0.91% during trading on Friday, hitting $192.19. 555,710 shares of the stock traded hands. The firm’s 50-day moving average is $183.92 and its 200 day moving average is $176.00. Illumina has a 52 week low of $119.37 and a 52 week high of $199.95. The stock has a market cap of $28.06 billion, a P/E ratio of 38.56 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.86 earnings per share. Equities research analysts forecast that Illumina will post $3.65 earnings per share for the current fiscal year.
In other news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $197.00, for a total transaction of $316,973.00. Following the completion of the transaction, the senior vice president now directly owns 9,037 shares in the company, valued at $1,780,289. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now owns 534,176 shares of the company’s stock, valued at $91,221,235.52. The disclosure for this sale can be found here. Insiders sold 138,185 shares of company stock valued at $25,063,480 over the last quarter. Corporate insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.